Open Access Articles- Top Results for SR-142,948


Systematic (IUPAC) name
2-([5-(2,6-dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino)adamantane-2-carboxylic acid
Clinical data
PubChem CID 5311451
IUPHAR ligand 1580
ChemSpider 4470937 7pxY
Chemical data
Formula C39H51N5O6
685.850 g/mol
 14pxY (what is this?)  (verify)

SR-142,948 is a drug used in scientific research which is a non-peptide antagonist selective for the neurotensin receptors, although not selective between subtypes.[1] It has been used to study the role of neurotensin in the regulation of dopamine receptor activity[2][3][4][5] and glutamate signalling in the brain,[6][7] and in animal studies SR-142,948 blocked the effects of stimulant drugs,[8] including MDMA.[9]


  1. Nalivaiko E, Michaud JC, Soubrié P, Le Fur G (October 1998). "Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons". Neuroscience 86 (3): 799–811. PMID 9692718. doi:10.1016/S0306-4522(98)00084-0. 
  2. Alonso R, Gnanadicom H, Fréchin N, Fournier M, Le Fur G, Soubrié P (March 1999). "Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain". The European Journal of Neuroscience 11 (3): 967–74. PMID 10103090. doi:10.1046/j.1460-9568.1999.00506.x. 
  3. Matsuyama S, Higashi H, Maeda H, Greengard P, Nishi A (April 2002). "Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors". Journal of Neurochemistry 81 (2): 325–34. PMID 12064480. doi:10.1046/j.1471-4159.2002.00822.x. 
  4. Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF (June 2002). "The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area". Naunyn-Schmiedeberg's Archives of Pharmacology 365 (6): 427–33. PMID 12070755. doi:10.1007/s00210-002-0574-6. 
  5. Panayi F, Colussi-Mas J, Lambás-Señas L, Renaud B, Scarna H, Bérod A (May 2005). "Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization". Neuropsychopharmacology 30 (5): 871–9. PMID 15637639. doi:10.1038/sj.npp.1300638. 
  6. Matsuyama S, Fukui R, Higashi H, Nishi A (September 2003). "Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling". The European Journal of Neuroscience 18 (5): 1247–53. PMID 12956723. doi:10.1046/j.1460-9568.2003.02859.x. 
  7. Yin HH, Adermark L, Lovinger DM (January 2008). "Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling". Neuropharmacology 54 (1): 79–86. PMC 2697967. PMID 17675102. doi:10.1016/j.neuropharm.2007.06.004. 
  8. Reynolds SM, Geisler S, Bérod A, Zahm DS (July 2006). "Neurotensin antagonist acutely and robustly attenuates locomotion that accompanies stimulation of a neurotensin-containing pathway from rostrobasal forebrain to the ventral tegmental area". The European Journal of Neuroscience 24 (1): 188–96. PMID 16882016. doi:10.1111/j.1460-9568.2006.04791.x. 
  9. Marie-Claire C, Palminteri S, Romualdi P, Noble F (June 2008). "Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice". Neuropharmacology 54 (7): 1107–11. PMID 18410947. doi:10.1016/j.neuropharm.2008.03.001. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.